Ribosomal protection as a linezolid resistance mechanism in Mycobacterium abscessus
Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)
DOI: 10.1128/aac.01605-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Tobias Funck und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Linezolid, Mycobacterium abscessus, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, Boehringer Ingelheim Fonds.
Abstract (Originalsprache)
Mycobacterium abscessus has emerged as a significant pulmonary pathogen characterized by its resistance to most first-line antimycobacterial drugs. Recent investigations have highlighted the clinical efficacy of including the oxazolidinone antibiotic linezolid in M. abscessus combination therapies, despite moderate resistance frequently being observed in patient isolates. Even with the potential usefulness of linezolid, the mechanisms that drive linezolid resistance in M. abscessus remain poorly understood. In several bacterial pathogens, including Mycobacterium tuberculosis , ATP-binding cassette (ABC) family proteins of the F subtype (ABC-F) have been found to confer antibiotic resistance to ribosome-targeting antibiotics, including linezolid. Here, we identified an M. abscessus ABC-F protein, MAB_2736c, that causes specific resistance to antibiotics that bind the 50S ribosomal subunit, including linezolid, macrolides, and chloramphenicol. These results demonstrate that targeting ABC-F proteins could help combat intrinsic resistance to several ribosome-targeting antibiotics in mycobacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital & German Center of Infection Research partner site, Heidelberg, Germany.
- Institute of Medical Microbiology, University of Lübeck & University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
ORCID-Profile: Tobias Funck, Kerry McGowen, Mark R Sullivan, Claudia M Denkinger, Eric J Rubin
Förderung
- NIGMS NIH HHS
- NIH HHS
- Boehringer Ingelheim Fonds
- Damon Runyon Cancer Research Foundation
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Funck, T., McGowen, K., Sullivan, M. R., Zinga, S., Wolf, I. D., Nurjadi, D., Denkinger, C. M., & Rubin, E. J. (2026). Ribosomal protection as a linezolid resistance mechanism in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.01605-25
Vancouver
Funck T, McGowen K, Sullivan MR, Zinga S, Wolf ID, Nurjadi D, et al. Ribosomal protection as a linezolid resistance mechanism in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.01605-25
BibTeX
@article{Funck2026,
author = {Funck, Tobias and McGowen, Kerry and Sullivan, Mark R and Zinga, Samuel and Wolf, Ian D and Nurjadi, Dennis and Denkinger, Claudia M and Rubin, Eric J},
title = {Ribosomal protection as a linezolid resistance mechanism in Mycobacterium abscessus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {4},
doi = {10.1128/aac.01605-25}
}
EUVIMED